More reasons to smile
By Path
Read the original here: More reasons to smile
|
By AIDS.gov
See more here: General Information Guide Now Available to Help You Navigate AIDS 2012
By AIDS.gov
Read the original here: HIV Vaccine Awareness Day: Moving toward a safe and effective preventive…
By GHHub
PLoS Neglected Tropical Diseases: Dengue Deaths in Puerto Rico: Lessons Learned from the 2007 Epidemic.
By GHHub
PLoS Neglected Tropical Diseases: A Research Agenda for Helminth Diseases of Humans: Towards Control and Elimination.
GlobalPost’s “Global Pulse” blog reports on a potential public-private partnership that aims to bring tuberculosis (TB) vaccine trials to the gold mines of Southern Africa, where, “[f]or every 100,000 workers …, 3,000 have tuberculosis, and many have often-fatal, drug-resistant strains of TB.” The blog writes that mining company “Anglo American announced Tuesday at the GBCHealth Conference [in New York] that it has agreed in principle to make its mines available for TB vaccine trials organized by Aeras, a non-profit that has 12 TB vaccine candidates now in various stages of research,” noting, “No formal agreement has been reached, but Anglo American’s spokesman vowed to make it happen.”
AIDS activists in Uganda are worried about a proposed reduction in the country’s health budget, as Parliament begins “a months-long budgeting process for the … next fiscal year,” VOA News reports. “AIDS activists have expressed concern that Uganda’s proposed budget for the next fiscal year includes a six percent cut in health funding to $307.5 million,” which “is less than 10 percent of the country’s overall budget,” the news service writes. Joshua Wamboga of The AIDS Support Organization said a lack of financial commitment from the government could undermine efforts to fight HIV/AIDS in the country, VOA notes, adding, “Government officials said the cut to the health budget reflects construction projects in that sector that have been completed and no longer require funding.” According to VOA, “The budget is months away from being finalized and activists hope there is still time to increase funds” (Green, 5/15).
By SciDev.net
Vietnam is seeking help from experts in Australia to reduce its levels of tuberculosis, one of the highest in Asia.
Image Credit: lilivanili Three new articled published this week in PLoS Medicine, including two magazine pieces on R&D: Diana Gibb and colleagues investigate the effect of in utero tenofovir exposure by analysing the pregnancy and infant outcomes of HIV-infected women enrolled in the DART trial. As part of a cluster of articles leading up to the 2012 World Health Report and critically reflecting on the theme of “no health without research,” Suerie Moon and colleagues argue for a global health R&D treaty to improve innovation in new medicines and strengthening affordability, sustainable financing, efficiency in innovation, and equitable health-centered governance. John-Arne Røttingen and Claudia Chamas, chairs of the the Consultative Expert Working Group on Research and Development (CEWG), summarize their recent report recommending to the World Health Assembly that a global health R&D convention be developed. Remember you can comment on, annotate and rate any PLoS Medicine article and see the views, citations and other indications of impact of an article on that articles metrics tab.
The House Appropriations Committee voted on its fiscal year (FY) 2013 State and Foreign Operations Appropriations bill Wednesday and released a report that clarifies its funding intentions for key global health programs. The bill includes $5.542 billion for global AIDS funding through the State Department, and the report specifies $4.243 billion to support the U.S. (Read more…)
By PIH
A new study finds that community health workers raised HIV drug adherence rates to some of the highest in the world.
By AIDS.gov
See original here: HRSA Seeks Public Input on Ryan White Reauthorization
In this Wall Street Journal opinion piece, Jay Winsten, associate dean at the Harvard School of Public Health, and Trish Stroman, a principal at the Boston Consulting Group, examine “the emergence in Southeast Asia of malarial parasites resistant to artemisinin — the current gold-standard drug for treating the disease,” writing it “poses grave new challenges.” Winsten and Stroman recount a brief history of artemisinin resistance in the region and note, “While many affected countries in the region are taking swift countermeasures, the situation remains serious in Burma,” also known as Myanmar.
Clinical trials are underway to test an azithromycin-based combination treatment for pregnant women, “which could tackle some of the leading preventable causes of death for babies in sub-Saharan Africa,” according to researchers from the London School of Hygiene & Tropical Medicine (LSHTM), who published a report on Wednesday in the Journal of the American Medical Association (JAMA) showing that “[a] large number of pregnant women in sub-Saharan Africa are infected with both malaria and sexually transmitted/reproductive tract infections (STIs/RTIs),” AlertNet reports (Mollins, 5/15). “The researchers looked at 171 studies from sub-Saharan Africa over a 20-year period, which showed whether women attending antenatal clinics were infected with malaria, or with a range of sexually transmitted and reproductive tract infections — syphilis, gonorrhea, chlamydia and bacterial and parasitic infections of the vagina,” IRIN writes, adding, “If left untreated, these can lead to miscarriages, stillbirths, premature births and low birthweight babies” (5/16).
